Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Haruaki Nobori

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Antiviral Research|May 15, 2018
Identification of Compound-B, a novel anti-dengue virus agent targeting the non-structural protein 4AHaruaki Nobori, Shinsuke Toba, Ryu Yoshida, et al.
Antiviral Research|September 4, 2025
Ensitrelvir suppresses prolonged olfactory abnormalities derived from SARS-CoV-2 infection in hamstersRyoichi Tashima, Takayuki Kuroda, Haruaki Nobori, et al.
Japanese Journal of Infectious Diseases|August 3, 2018
Single Amino Acid Mutation in Dengue Virus NS4B Protein Has Opposing Effects on Viral Proliferation in Mammalian and Mosquito CellsJumpei Fujiki, Haruaki Nobori, Akihiko Sato, et al.
Viruses|October 28, 2023
Pharmacokinetic and Pharmacodynamic Analysis of the 3CL Protease Inhibitor Ensitrelvir in a SARS-CoV-2 Infection Mouse ModelKeita Fukao, Haruaki Nobori, Takayuki Kuroda, et al.
Antiviral Research|November 7, 2020
Identification of quinolone derivatives as effective anti-Dengue virus agentsHaruaki Nobori, Kentaro Uemura, Shinsuke Toba, et al.
Virus Research|February 13, 2016
Generation of recombinant rabies viruses encoding NanoLuc luciferase for antiviral activity assaysPaulina Duhita Anindita, Michihito Sasaki, Haruaki Nobori, et al.
Biochemical and Biophysical Research Communications|January 23, 2023
Ensitrelvir is effective against SARS-CoV-2 3CL protease mutants circulating globallySho Kawashima, Yuki Matsui, Takumi Adachi, et al.
Antiviral Research|March 1, 2024
Prophylactic effect of ensitrelvir in mice infected with SARS-CoV-2Haruaki Nobori, Keiko Baba, Takayuki Kuroda, et al.
Virology|February 26, 2017
Discovery of a novel antiviral agent targeting the nonstructural protein 4 (nsP4) of chikungunya virusYuji Wada, Yasuko Orba, Michihito Sasaki, et al.
Antiviral Research|October 30, 2024
Oral 3CL protease inhibitor ensitrelvir suppressed SARS-CoV-2 shedding and infection in a hamster aerosol transmission modelMasaaki Nakashima, Haruaki Nobori, Takayuki Kuroda, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Antiviral Research|May 15, 2018
Identification of Compound-B, a novel anti-dengue virus agent targeting the non-structural protein 4AHaruaki Nobori, Shinsuke Toba, Ryu Yoshida, et al.
Antiviral Research|September 4, 2025
Ensitrelvir suppresses prolonged olfactory abnormalities derived from SARS-CoV-2 infection in hamstersRyoichi Tashima, Takayuki Kuroda, Haruaki Nobori, et al.
Japanese Journal of Infectious Diseases|August 3, 2018
Single Amino Acid Mutation in Dengue Virus NS4B Protein Has Opposing Effects on Viral Proliferation in Mammalian and Mosquito CellsJumpei Fujiki, Haruaki Nobori, Akihiko Sato, et al.
Viruses|October 28, 2023
Pharmacokinetic and Pharmacodynamic Analysis of the 3CL Protease Inhibitor Ensitrelvir in a SARS-CoV-2 Infection Mouse ModelKeita Fukao, Haruaki Nobori, Takayuki Kuroda, et al.
Antiviral Research|November 7, 2020
Identification of quinolone derivatives as effective anti-Dengue virus agentsHaruaki Nobori, Kentaro Uemura, Shinsuke Toba, et al.
Virus Research|February 13, 2016
Generation of recombinant rabies viruses encoding NanoLuc luciferase for antiviral activity assaysPaulina Duhita Anindita, Michihito Sasaki, Haruaki Nobori, et al.
Biochemical and Biophysical Research Communications|January 23, 2023
Ensitrelvir is effective against SARS-CoV-2 3CL protease mutants circulating globallySho Kawashima, Yuki Matsui, Takumi Adachi, et al.
Antiviral Research|March 1, 2024
Prophylactic effect of ensitrelvir in mice infected with SARS-CoV-2Haruaki Nobori, Keiko Baba, Takayuki Kuroda, et al.
Virology|February 26, 2017
Discovery of a novel antiviral agent targeting the nonstructural protein 4 (nsP4) of chikungunya virusYuji Wada, Yasuko Orba, Michihito Sasaki, et al.
Antiviral Research|October 30, 2024
Oral 3CL protease inhibitor ensitrelvir suppressed SARS-CoV-2 shedding and infection in a hamster aerosol transmission modelMasaaki Nakashima, Haruaki Nobori, Takayuki Kuroda, et al.
Pageof 3